**Supplementary Table S1. Recommended TSB Levels for Phototherapy**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Postnatal Age (hours)** | **AAP 2004a**  **Medium Risk**  **(mg/dL)** | **95th Percentile**  **on Bhutani Nomogramb**  **(mg/dL)** | **NICEc**  **(mg/dL)** | **WHOd**  **(mg/dL)** | **Current**  **(mg/dL)** |
| 24 | ≥9.9 | ≥7.8 | >11.7 | ≥15.0 | ≥12 |
| 30 | ≥10.8 | ≥9.5 | >12.4 | ≥15.0 | ≥12 |
| 36 | ≥11.7 | ≥11.1 | >13.2 | ≥15.0 | ≥12 |
| 42 | ≥12.4 | ≥12.4 | >13.9 | ≥15.0 | ≥12 |
| 48 | ≥13.1 | ≥13.2 | >14.6 | ≥18.0 | ≥12 |
| 54 | ≥13.9 | ≥14.1 | >15.3 | ≥18.0 | ≥12 |
| 60 | ≥14.6 | ≥15.2 | >16.1 | ≥18.0 | ≥12 |
| 66 | ≥15.1 | ≥15.5 | >16.8 | ≥18.0 | ≥12 |
| 72 | ≥15.5 | ≥15.9 | >17.5 | ≥18.0 | ≥12 |
| 78 | ≥16.1 | ≥16.3 | >18.2 | ≥18.0 | ≥12 |
| 84 | ≥16.6 | ≥16.7 | >19.0 | ≥18.0 | ≥12 |
| 90 | ≥17.1 | ≥17.1 | >19.7 | ≥18.0 | ≥12 |
| 96 | ≥17.5 | ≥17.4 | >20.5 | ≥18.0 | ≥12 |
| 102 | ≥17.8 | ≥17.5 | >20.5 | ≥18.0 | ≥12 |
| 108 | ≥18.0 | ≥17.5 | >20.5 | ≥18.0 | ≥12 |
| 114 | ≥18.0 | ≥17.6 | >20.5 | ≥18.0 | ≥12 |
| 120+ | ≥18.0 | ≥17.7 | >20.5 | ≥18.0 | ≥12 |

aAmerican Academy of Pediatrics (AAP). Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. *Pediatrics* 2004;114:297-316.

bBhutani VK, Johnson L, Sivieri EM. Predictive ability of a predischarge hour-specific serum bilirubin for subsequent significant hyperbilirubinemia in healthy term and near-term newborns. *Pediatrics*. 1999;103:6-14.

cNational Institute for Health and Clinical Excellence (NICE). Neonatal jaundice. (Clinical guideline 98.), 2010. [www.nice.org.uk/CG98](http://www.nice.org.uk/CG98).

dWorld Health Organisation (WHO): *Pocket Book of Hospital Care for Children: Guidelines for the Management of Common Childhood Illnesses*. 2nd edition. Geneva: WHO, 2013.